Annual Cash & Cash Equivalents
$129.79 M
+$103.70 M+397.46%
December 31, 2023
Summary
- As of February 7, 2025, GPCR annual cash & cash equivalents is $129.79 million, with the most recent change of +$103.70 million (+397.46%) on December 31, 2023.
- During the last 3 years, GPCR annual cash & cash equivalents has risen by +$113.44 million (+693.74%).
- GPCR annual cash & cash equivalents is now at all-time high.
Performance
GPCR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$172.13 M
-$209.50 M-54.90%
September 30, 2024
Summary
- As of February 7, 2025, GPCR quarterly cash and cash equivalents is $172.13 million, with the most recent change of -$209.50 million (-54.90%) on September 30, 2024.
- Over the past year, GPCR quarterly cash and cash equivalents has increased by +$121.49 million (+239.94%).
- GPCR quarterly cash and cash equivalents is now -54.90% below its all-time high of $381.63 million, reached on June 30, 2024.
Performance
GPCR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
GPCR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +397.5% | +239.9% |
| 3 y3 years | +693.7% | +239.9% |
| 5 y5 years | +693.7% | +239.9% |
GPCR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +397.5% | -54.9% | +559.7% |
| 5 y | 5-year | at high | +693.7% | -54.9% | +559.7% |
| alltime | all time | at high | +693.7% | -54.9% | +559.7% |
Structure Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $172.13 M(-54.9%) |
| Jun 2024 | - | $381.63 M(+290.1%) |
| Mar 2024 | - | $97.83 M(-24.6%) |
| Dec 2023 | $129.79 M | $129.79 M(+156.3%) |
| Sep 2023 | - | $50.64 M(+24.7%) |
| Jun 2023 | - | $40.59 M(-67.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $126.49 M(+384.8%) |
| Dec 2022 | $26.09 M(-75.2%) | $26.09 M(-7.1%) |
| Sep 2022 | - | $28.09 M(-73.3%) |
| Dec 2021 | $105.31 M(+544.0%) | - |
| Dec 2021 | - | $105.31 M |
| Dec 2020 | $16.35 M | - |
FAQ
- What is Structure Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Structure Therapeutics?
- What is Structure Therapeutics annual cash & cash equivalents year-on-year change?
- What is Structure Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Structure Therapeutics?
- What is Structure Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Structure Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of GPCR is $129.79 M
What is the all time high annual cash & cash equivalents for Structure Therapeutics?
Structure Therapeutics all-time high annual cash & cash equivalents is $129.79 M
What is Structure Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, GPCR annual cash & cash equivalents has changed by +$103.70 M (+397.46%)
What is Structure Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GPCR is $172.13 M
What is the all time high quarterly cash and cash equivalents for Structure Therapeutics?
Structure Therapeutics all-time high quarterly cash and cash equivalents is $381.63 M
What is Structure Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, GPCR quarterly cash and cash equivalents has changed by +$121.49 M (+239.94%)